MDL-811

MDL-811 is a selective allosteric activator of SIRT6 with an EC50 of 5.7 μM. MDL-811 possesses anti-inflammatory, antitumor, and neuroprotective activities. MDL-811 can be used for the research of diseases such as colorectal cancer and ischemic stroke[1][2].

Product Specifications

CAS Number

[2275619-98-0]

UNSPSC

12352005

Target

Cytochrome P450; Interleukin Related; Sirtuin

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Epigenetics; Immunology/Inflammation; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer; Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/mdl-811.html

Purity

99.68

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC(C=C(C(Br)=C1)F)=C1NS(=O)(C2=C(C=C(C=C2)NS(=O)(C3=CC(Cl)=CC(Cl)=C3)=O)CN4[C@@H](COCC4)C)=O

Molecular Formula

C25H25BrCl2FN3O5S2

Molecular Weight

681.42

References & Citations

[1]Jialin Shang, et al. Small-molecule activating SIRT6 elicits therapeutic effects and synergistically promotes anti-tumor activity of vitamin D3 in colorectal cancer. Theranostics. 2020 Apr 27;10 (13) :5845-5864.|[2]He T, et al. A novel SIRT6 activator ameliorates neuroinflammation and ischemic brain injury via EZH2/FOXC1 axis. Acta Pharm Sin B. 2021 Mar;11 (3) :708-726.